Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:260473.
doi: 10.1155/2012/260473. Epub 2012 Oct 2.

IL-17 and IL-22 in cerebrospinal fluid and plasma are elevated in Guillain-Barré syndrome

Shujuan Li  1 , Ming Yu, Haifeng Li, Hongliang Zhang, Yanfang Jiang
Affiliations

IL-17 and IL-22 in cerebrospinal fluid and plasma are elevated in Guillain-Barré syndrome

Shujuan Li et al. Mediators Inflamm. 2012.

Abstract

Guillain-Barré syndrome (GBS) is an acute autoimmune-mediated inflammatory demyelinating disease that causes rapidly progressing paralysis and occasionally respiratory failure. We hypothesized that interleukin (IL)-17 and IL-22 are elevated in GBS and participate in the autoimmune inflammatory response of GBS. We used sandwich enzyme-linked immunosorbent assay (ELISA) to measure the IL-17 and IL-22 levels in the CSF, and plasma from 22 GBS patients at the acute phase and 18 healthy controls (HC). The results show that CSF and plasma levels of IL-17 and IL-22 are elevated in GBS patients compared with HC. IL-17 and IL-22 levels in CSF, respectively, are correlated with GBS disability scale scores (GDSs). Meanwhile, IL-17 and IL-22 levels in CSF, IL-22 in CSF, and plasma of GBS patients have positive correlation, respectively. The increased levels of IL-17 and IL-22 in CSF may be explained by the disruption of blood-brain barrier (BBB) and peripheral nervous system (PNS) local inflammation in GBS. Meanwhile, the elevated levels of these two cytokines in plasma suggest the activation of Th17 and Th22 cells in the systemic immune response of GBS. Our data provide preliminary evidence that GBS is associated with high levels of IL-17 and IL-22 in CSF and plasma. These cytokines display pathogenic potential and may serve as useful biomarkers for GBS.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CSF and plasma levels of IL-17 and IL-22 in GBS (n = 22) and healthy controls (HC, n = 18). Statistical significance was indicated: *P < 0.05, **P < 0.001. Each circle = single individual, horizontal bars = mean.
Figure 2
Figure 2
The correlations of CSF and plasma levels of IL-17 and IL-22 with GBS disability scale scores (GDSs). The Spearman correlation coefficient was used to analyze between two sets. Each circle = single individual; lines = linear approximation.
Figure 3
Figure 3
The correlations of CSF and plasma levels of IL-17 and IL-22. The Pearson correlation coefficient was used to analyze between two sets. Each circle = single individual; lines = linear approximation.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hughes RA, Cornblath DR. Guillain-Barré syndrome. The Lancet. 2005;366(9497):1653–1666. - PubMed
    1. Cosi V, Versino M. Guillain-Barré syndrome. Neurological Sciences. 2006;27(supplement 1):s47–s51. - PubMed
    1. Van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. The Lancet Neurology. 2008;7(10):939–950. - PubMed
    1. Perry JR, Fung A, Poon P, Bayer N. Magnetic resonance imaging of nerve root inflammation in the Guillain-Barre syndrome. Neuroradiology. 1994;36(2):139–140. - PubMed
    1. Hughes RA, Raphaël JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews. 2006;(1):p. CD002063. - PubMed

Publication types